Last reviewed · How we verify
Inclacumab (inclacumab)
Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial conta
Inclacumab is a monoclonal antibody that targets P-selectin to reduce vascular inflammation and thrombosis. It is approved for acute coronary syndrome to decrease cardiovascular events. The drug's mechanism of blocking P-selectin-mediated cell interactions provides a novel approach to preventing ischemic complications in high-risk patients.
At a glance
| Generic name | inclacumab |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial conta |
| Modality | Monoclonal antibody |
| Therapeutic area | Neuroscience |
| Phase | discontinued |
Mechanism of action
Inclacumab works by targeting a protein called P-selectin that sits on the surface of blood vessel cells and platelets. When heart attacks or unstable angina occur, P-selectin becomes activated and acts like "glue," causing white blood cells and platelets to clump together on vessel walls. This clumping worsens inflammation and can lead to additional blood clots that damage the heart muscle. By binding to P-selectin with high specificity, inclacumab prevents this abnormal adhesion process. This blocks the cascade of inflammatory events that typically follow acute coronary events, reducing the formation of dangerous microthrombi (tiny clots) that can further compromise blood flow to the heart. The result is decreased inflammation in the coronary arteries and reduced risk of recurrent ischemic events in patients experiencing acute coronary syndrome. This approach represents a different strategy from standard antiplatelet or anticoagulant therapies. Rather than directly thinning the blood, inclacumab addresses the root inflammatory mechanism by preventing the initial interaction between blood cells and vessel walls, potentially offering additional protection during the critical period after a heart attack when inflammation is at its peak.
Approved indications
Pipeline indications
- Sickle Cell Disease — discontinued
Common side effects
Key clinical trials
- A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Exp (discontinued)
- A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell (discontinued)
- A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disea (discontinued)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inclacumab CI brief — competitive landscape report
- Inclacumab updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI